Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4757 - Use of Nuclear-Localized Androgen Receptor Splice Variant 7 Protein in CTCs after 1st Androgen Receptor Signaling Inhibitor (ARSi) as a Predictive Biomarker for Overall Survival on a Second ARSi or Taxane Chemotherapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy

Tumour Site

Prostate Cancer

Presenters

Howard Scher

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

H.I. Scher1, R.P. Graf2, M. Hulling1, E. Carbone1, R. Dittamore2

Author affiliations

  • 1 Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 2 Translational Research, Epic Sciences, Inc., San Diego/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4757

Background

In the U.S., most mCRPC patients will receive an ARSi (abiraterone, enzalutamide) in 1st line. More than 60% will receive a second, sequential ARSi (A-A) as opposed to ARSi then Taxane (A-T). No randomized studies exist comparing A-A and A-T. Recent real-world cohort risk-adjusted analyses were not able to discern differences in overall survival (OS) between A-A and A-T, despite a wide range of observed outcomes within groups. Using a cross-sectional cohort of standard of care in a tertiary center, we sought to determine if observations were consistent with community, and evaluate if nuclear AR-V7 could have additive effect on OS, specifically post-ARSi failure.

Methods

We previously reported utility of nuclear AR-V7 in two cross-sectional cohorts (Scher et al 2016 and Scher et al 2018). Blood was drawn from mCRPC patients prior to new line of therapy, AR-V7 testing by Epic Sciences, and therapy choice by physician without knowledge of AR-V7 status. OS data was updated, and a subset of these combined cohorts were analyzed (n = 148): those who had failed an ARSi, and were about to go onto a second ARSi (n = 73) or taxane (n = 75). A risk score was used to adjust for underlying patient imbalances and therapy choice propensity.

Results

75 of 148 (51%) received A-T and 73 of 148 (49%) received A-A. Adjusting for patient risk, a discernable difference in OS was not detected (HR: 1.16, CI: 0.73 – 1.85, p = 0.52). Incorporating AR-V7, there was a significant interaction between positivity for AR-V7 and OS on taxanes (HR: 0.16, CI: 0.052 – 0.52, p = 0.0020). In risk-matched analysis, there was a significant difference in OS between AR-V7(+) patients on taxanes vs. ARSi (11.6mo vs. 5.5mo, p = 0.0029).

Conclusions

Sequential ARSi use in the U.S. is common. Adjusting for patient risk and physician therapy choice, AR-V7 use after ARSi failure identifies patients who would live longer on taxanes vs. ARSi. Physician intuition alone was not sufficient to achieve predictive effect of AR-V7.

Clinical trial identification

Legal entity responsible for the study

MSKCC.

Funding

NIH/NCI P50-CA92629 SPORE in Prostate Cancer, NIH/NCI Cancer Center Support Grant P30-CA008748, NIH grant R01-CA207220, Department of Defense Prostate Cancer Research Program (PC121111 and PC131984), Prostate Cancer Foundation Challenge Award, and David H. Koch Fund for Prostate Cancer Research.

Editorial Acknowledgement

Disclosure

H.I. Scher: Consultant: Sanofi, Clovis, Janssen, Pfizer; Grant/research support to MSK: Innocrin, Janssen; Board of directors: Asterias Biotheraputics; Advisory board: WCG Oncology. R.P. Graf: Employee: Epic Sciences, Inc. R. Dittamore: Employee of Epic Sciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.